Trend of toxicity and inflammatory markers. (A) The toxicity grade trend for each patient, including responders and nonresponders to anakinra. (B) LDH, ferritin, and CRP trends and associations with response to anakinra. †Fatal event (cause). In patient 5, ICH was present before anakinra initiation. In both patients treated for HLH, the latter was characterized by pancytopenia, elevated serum ferritin and triglyceride levels, decreased fibrinogen levels, and bone marrow evidence of hemophagocytosis. None of the 4 patients who responded to anakinra had LDH >500 U/L, ferritin >10 000 mg/L, or CRP >300 mg/L. Because of the small sample size, differences did not reach statistical significance (P = .55 [ferritin]; P = .77 [CRP]; P = .26 [LDH]). ICH, intracranial hemorrhage; PD, progressive disease.